Lyra Therapeutics IncNASDAQ:LYRA
- LAST PRICE5.2500
- TODAY'S CHANGE (%)0.0200 (0.3824%)
- Bid / Lots5.2100/ 4
- Ask / Lots5.2600/ 2
- Open / Previous Close5.2000 / 5.2300
- Day Range
- 52 Week Range
- Volume24,463
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LYRA |
|---|---|---|
| 09:32 ET | 381 | 5.2 |
| 09:34 ET | 2100 | 5.215 |
| 09:38 ET | 10838 | 5.15 |
| 09:39 ET | 100 | 5.15 |
| 09:41 ET | 700 | 5.13 |
| 09:45 ET | 800 | 5.17 |
| 10:03 ET | 100 | 5.21 |
| 10:12 ET | 500 | 5.19 |
| 10:14 ET | 100 | 5.23 |
| 10:17 ET | 100 | 5.25 |
| 10:19 ET | 312 | 5.25 |
| 10:21 ET | 802 | 5.25 |
| 10:24 ET | 100 | 5.2201 |
| 10:26 ET | 900 | 5.215 |
| 10:35 ET | 100 | 5.2 |
| 10:37 ET | 100 | 5.23 |
| 10:39 ET | 100 | 5.23 |
| 10:42 ET | 100 | 5.23 |
| 10:44 ET | 1000 | 5.215 |
| 10:48 ET | 100 | 5.26 |
| 10:50 ET | 200 | 5.25 |
Mar 26, 2024
Thinking about buying stock in GameStop, Equinix, Lyra Therapeutics, Krystal Biotech, or KULR Technology?, from 9:31AM ET on Tuesday Mar 26, 2024 by Dow Jones
9:31AM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lyra Therapeutics Inc | 312.5M | -4.0x | --- |
Q32 Bio Inc | 317.2M | -0.8x | --- |
ATAI Life Sciences NV | 310.5M | -6.6x | --- |
Atea Pharmaceuticals Inc | 311.4M | -2.3x | --- |
Terns Pharmaceuticals Inc | 307.1M | -3.6x | --- |
Fractyl Health Inc | 301.2M | -3.1x | --- |
Company Information
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.
Contact Information
- Headquarters
- 480 Arsenal WayWATERTOWN, MA, United States 02472
- Phone
- 617-373-4600
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Harlan Waksal
- President, Chief Executive Officer, Director
- Maria Palasis
- Chief Financial Officer, Treasurer, Secretary
- Jason Cavalier
- Senior Vice President - Commercial Strategy and Market Development
- Corinne Noyes
- Senior Vice President - Technical Operations
- Robert Richard
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $312.5M |
|---|---|
Revenue (TTM) | $1.6M |
Shares Outstanding | 59.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.30 |
EPS | $-1.32 |
Book Value | $1.56 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | 200.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -4,308.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
